Surgery Websites
Thoracic Oncology Lab »  Alumni »  Principal Investigators »  Hassan Lemjabbar-Alaoui. Ph.D.
Hassan Lemjabbar-Alaoui, Ph.D.

Hassan Lemjabbar-Alaoui, Ph.D.

  • Professor of Surgery
  • Division of Adult Cardiothoracic Surgery

Contact Information

2340 Sutter Street N-224, Box 1724
University of California, San Francisco
San Francisco, CA 94143-1724
415-476-9303 Phone
[email protected]
Open Popup

University of Paris VII, B.S., Biology, 1988-1989

University of Paris VII, M.S.,  Molecular Biology and Immunology, 1989-1991

University of Paris VI, M.S., Biochemistry, 1991-1992

University of Paris VI, Post-Master University Diploma (DU), Clinical Pharmacokinetics and Therapeutics, 1992-1993

University of Paris XIII, Post-Master DE.A of Science, Medical and Biological Engineering, 1993-1994

University of Paris XII, Ph.D.,  Molecular and Cell Biology, 1994-1997

  • 1997-1998, Scientist, Naturalia Biologia. Paris, France
  • 1998-2001, Postdoctoral Researcher, Department of Anatomy, UCSF
  • Thoracic Oncology Program
  • Thoracic Oncology Laboratory
  • Member, UCSF Helen Diller Family Comprehensive Cancer Center
  • UCSF Department of Surgery
  • Biomarkers for early cancer detection
  • DNA repair mechanisms
  • Drug resistance mechanisms
  • Embryonic signaling pathways such as Wnt signaling
  • Novel targeted therapies
  • Role of the epidermal growth factor receptor (EGFR)
  • Sulf-1 and Sulf-2

Hassan Lemjabbar-Alaoui, Ph.D. is a biomedical scientist and Principal Investigator in the Thoracic Oncology Laboratory. Dr. Alaoui received his Ph.D. from the University of Paris XII.  Since receiving his Ph.D. from the University of Paris XII, he has focused his research work on deciphering the molecular mechanisms of lung cancer and other thoracic malignancies, and discovering novel targeted therapies and diagnostic biomarkers with clinical utility for the treatment of these diseases. Dr. Alaoui began these studies in 1997 as a postdoctoral fellow/Assistant Research Anatomist in Dr. Carol Basbaum's lab at UCSF, and continued them as an Assistant Professor of Anatomy at UCSF. 

Dr. Alaoui has also been the recipient of numerous awards including the prestigious National Institutes of Health/(NIH-NCI)/ U01 grant, the Doctors Cancer Foundation award, the Pfizer-CTI Research Program award, and the American Cancer Society. 

Dr. Alaoui's research is focused on elucidating diagnostic biomarkers and developing novel targeted therapies for treatment of lung cancer, mesothelioma and esophageal cancer. My lab seeks to gain a keen understanding of the molecular mechanisms underlying these diseases. Our projects include:

  1. Investigating the role of extracellular heparan sulfate degrading sulfatases (SULFs) in tumorigenesis, and finding novel ways to target them.
  2. Discovering novel blood biomarkers for early detection and stratification of thoracic malignancies.
  3. Elucidating the molecular mechanisms of multi-drug resistance in thoracic malignancies.
  4. Developing DNA repair inhibitors for thoracic malignancies, particularly small-molecule inhibitors, which hold great promise for damaging tumor cells.
  5. Adapting cAbl inhibitors, FDA-approved for the treatment of chronic myeloid leukemia (CML), for treatment of malignant mesothelioma, a devastating and currently incurable disease. 
Data provided by UCSF Profiles, powered by CTSI
  • Extracellular Sulfatases As Novel Biomarkers For Early Detection of Cancer
    Sponsor ID:
    Funding Period:
    Aug 2012
    Jun 2017
    Principal Investigator
Data provided by UCSF Profiles, powered by CTSI
  1. Yang YW, Jablons DM, Lemjabbar-Alaoui H. Extracellular sulfatases as potential blood-based biomarkers for early detection of lung cancer. Exp Lung Res. 2021 May-Aug; 47(6):261-279. View in PubMed
  2. Luo X, Campbell NA, He L, O'Brien DR, Singer MS, Lemjabbar-Alaoui H, Ahn KS, Smoot R, Torbenson MS, Rosen SD, Roberts LR. Sulfatase 2 (SULF2) Monoclonal Antibody 5D5 Suppresses Human Cholangiocarcinoma Xenograft Growth Through Regulation of a SULF2-Platelet-Derived Growth Factor Receptor Beta-Yes-Associated Protein Signaling Axis. Hepatology. 2021 09; 74(3):1411-1428. View in PubMed
  3. Yang YW, Phillips JJ, Jablons DM, Lemjabbar-Alaoui H. Development of novel monoclonal antibodies and immunoassays for sensitive and specific detection of SULF1 endosulfatase. Biochim Biophys Acta Gen Subj. 2021 02; 1865(2):129802. View in PubMed
  4. Yang YW, Marrufo A, Chase J, Woodard GA, Jablons DM, Lemjabbar-Alaoui H. Ponatinib is a potential therapeutic approach for malignant pleural mesothelioma. Exp Lung Res. 2021 02; 47(1):9-25. View in PubMed
  5. Lemjabbar-Alaoui H, Peto CJ, Yang YW, Jablons DM. AMXI-5001, a novel dual parp1/2 and microtubule polymerization inhibitor for the treatment of human cancers. Am J Cancer Res. 2020; 10(8):2649-2676. View in PubMed
  6. View All Publications


Site Directory